Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) - Total Assets
Based on the latest financial reports, Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (301096) holds total assets worth CN¥3.80 Billion CNY (≈ $556.41 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore Hangzhou Bio-Sincerity Pharma-Tech Co.Lt cash debt coverage ratio to assess how comfortably operating cash covers total debt obligations.
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. - Total Assets Trend (2019–2025)
This chart illustrates how Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s total assets have evolved over time, based on quarterly financial data. See Hangzhou Bio-Sincerity Pharma-Tech Co.Lt book value and equity for net asset value and shareholders' equity analysis.
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. - Asset Composition Analysis
Current Asset Composition (December 2025)
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s total assets of CN¥3.80 Billion consist of 42.1% current assets and 57.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 7.9% |
| Accounts Receivable | CN¥467.21 Million | 12.7% |
| Inventory | CN¥176.44 Million | 4.8% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥89.80 Million | 2.4% |
| Goodwill | CN¥0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Hangzhou Bio-Sincerity Pharma-Tech Co.Lt.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s current assets represent 42.1% of total assets in 2025, a decrease from 61.5% in 2019.
- Cash Position: Cash and equivalents constituted 7.9% of total assets in 2025, down from 49.9% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 2.0% of total assets, a decrease from 15.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 12.7% of total assets.
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. Competitors by Total Assets
Key competitors of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biogen Inc
NASDAQ:BIIB
|
USA | $29.44 Billion |
|
Pfizer Inc
SA:PFIZ34
|
Brazil | R$207.62 Billion |
|
AstraZeneca PLC
NYSE:AZN
|
USA | $114.02 Billion |
|
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SHG:600436
|
China | CN¥18.38 Billion |
|
Aurora Optoelectronics Co Ltd
SHG:600666
|
China | CN¥2.22 Billion |
|
NanJing Pharmaceutical Co Ltd
SHG:600713
|
China | CN¥34.05 Billion |
|
Dimed S.A. Distribuidora de Medicamentos
SA:PNVL3
|
Brazil | R$3.66 Billion |
|
Firebrick Pharma Ltd
AU:FRE
|
Australia | AU$2.28 Million |
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.87 | 1.90 | 13.54 |
| Quick Ratio | 1.67 | 1.67 | 13.32 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥791.96 Million | CN¥763.84 Million | CN¥1.75 Billion |
Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. - Advanced Valuation Insights
This section examines the relationship between Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 2.64 |
| Latest Market Cap to Assets Ratio | 0.17 |
| Asset Growth Rate (YoY) | -0.9% |
| Total Assets | CN¥3.69 Billion |
| Market Capitalization | $616.96 Million USD |
Valuation Analysis
Below Book Valuation: The market values Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s assets below their book value (0.17x), which may indicate investor concerns about asset quality or future growth.
Slight Asset Contraction: Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.'s assets decreased by 0.9% over the past year, which may reflect streamlining or optimization of resources.
Annual Total Assets for Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. (2019–2025)
The table below shows the annual total assets of Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd. from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥3.69 Billion ≈ $539.42 Million |
-0.94% |
| 2024-12-31 | CN¥3.72 Billion ≈ $544.53 Million |
+1.42% |
| 2023-12-31 | CN¥3.67 Billion ≈ $536.91 Million |
+25.24% |
| 2022-12-31 | CN¥2.93 Billion ≈ $428.71 Million |
+0.17% |
| 2021-12-31 | CN¥2.92 Billion ≈ $428.00 Million |
+344.01% |
| 2020-12-31 | CN¥658.75 Million ≈ $96.40 Million |
+73.98% |
| 2019-12-31 | CN¥378.63 Million ≈ $55.41 Million |
-- |
About Hangzhou Bio-Sincerity Pharma-Tech Co.Ltd.
Hangzhou Bio-Sincerity Pharma-Tech Co.,Ltd. operates as a pharmaceutical technology research and development and services company in China. The company primarily provides drug research and development services; and the transformation of research and development technology results for various pharmaceutical, as well as pharmaceutical research and development investment companies. Its business cove… Read more